Lupus Nephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Receiver-operating characteristic curve analysis demonstrated that urinary CD11b was superior to CD16b, the scavenger receptor CD163, and monocyte chemotactic protein-1 for the prediction of proliferative LN.
|
30712924 |
2019 |
Lupus Nephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Combined utilization of untimed single urine of MCP-1 and TWEAK as a potential indicator for proteinuria in lupus nephritis: A case-control study.
|
29668584 |
2018 |
Lupus Nephritis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The levels of monocyte chemoattractant protein-1 (MCP-1) in the serum and urine of 72 SLE patients (27 with LN and 45 without LN involvement) and 30 healthy individuals were studied to establish their clinical significance.
|
29181621 |
2018 |
Lupus Nephritis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A combined model of uMCP-1 and uTWEAK showed an AUC of 0.887, sensitivity of 86.67% and specificity of 80.00% to discriminate active LN, and an AUC of 0.778, sensitivity of 75.00% and specificity of 81.82% to discriminate LN with poor outcome, which are better than the utility of any markers individually.
|
29451067 |
2018 |
Lupus Nephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
We investigated whether levels of urinary neutrophil gelatinase-associated lipocalin (NGAL), and monocyte chemoattractant protein 1 (MCP-1) are good biomarkers to differentiate patients with lupus nephritis among Latin-American systemic lupus erythematosus (SLE) patients.
|
29073812 |
2018 |
Lupus Nephritis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Conclusion Urinary KIM-1, NGAL, and MCP-1 levels were associated with kidney injury indices in lupus nephritis.
|
30020021 |
2018 |
Lupus Nephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our study identifies the gene expression profile for macrophages and demonstrated the induction of CCL2 and CD38 in macrophages from patients with LN.
|
29458096 |
2018 |
Lupus Nephritis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Results Urine and serum levels of CCL2, CCL5 and CXCL10 were elevated in active LN as compared with disease remission (best discrimination for urine CXCL10 and CCL2) and correlated with LN activity.
|
29653499 |
2018 |
Lupus Nephritis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Urinary AGP, ceruloplasmin, VCAM-1, MCP-1 and LPGDS levels were significantly higher in those patients with active LN than in non-LN patients [all corrected p values (p <sub>c</sub>) < 0.05] across both cohorts.
|
27590021 |
2017 |
Lupus Nephritis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The current meta-analysis suggests that the MCP-1-2518A/G polymorphism is associated with an increased risk of LN, especially in the American population.
|
29390552 |
2017 |
Lupus Nephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Objectives The renal activity index for lupus (RAIL) score was developed in children with lupus nephritis as a weighted sum of six urine biomarkers (UBMs) (neutrophil gelatinase-associated lipocalin, monocyte chemotactic protein 1, ceruloplasmin, adiponectin, hemopexin and kidney injury molecule 1) measured in a random urine sample.
|
28361601 |
2017 |
Lupus Nephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Dual blockade of CCL2 and CXCL12 can be as potent as CYC to suppress the progression of proliferative lupus nephritis probably because the respective chemokine targets mediate different disease pathomechanisms, i.e. systemic autoimmunity and peripheral tissue inflammation.
|
29111236 |
2017 |
Lupus Nephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Dual blockade of CCL2 and CXCL12 can be as potent as CYC to suppress the progression of proliferative lupus nephritis probably because the respective chemokine targets mediate different disease pathomechanisms, i.e. systemic autoimmunity and peripheral tissue inflammation.
|
27392463 |
2016 |
Lupus Nephritis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Association of monocyte chemoattractant protein 1 (MCP-1) gene polymorphism with lupus nephritis in Egyptian patients.
|
26429331 |
2015 |
Lupus Nephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Urinary HER-2 was increased in LN and reflected disease activity, and its levels correlated with those of 2 other recognized LN biomarkers, MCP-1 and VCAM-1.
|
26016809 |
2015 |
Lupus Nephritis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Mizoribine itself selectively attenuated the expression of MCP-1 both mRNA and protein levels in MCs treated with poly IC; that is, a possible model of 'pseudoviral' infection, which may be involved in the pathogenesis of lupus nephritis.
|
24134561 |
2014 |
Lupus Nephritis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Conversely, overexpression of CCL2 in lupus MSCs restored their immunoregulatory ability for B cells in vitro and ameliorated the pathology of lupus nephritis and serological changes in MRL/lpr mice in vivo.
|
25339674 |
2014 |
Lupus Nephritis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The aim of our study was to evaluate the possible association of the polymorphism -2518 of the MCP-1 gene with the risk of developing SLE, manifesting lupus nephritis (LN) and with other clinical features of SLE in an Argentinean population.
|
22466290 |
2012 |
Lupus Nephritis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
This meta-analysis on 3419 subjects indicates that no association exists between the MCP-1 -2518 A/G polymorphism and SLE or LN.
|
19941075 |
2010 |
Lupus Nephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
These findings support that MCP-1 -2518 G/G is associated with LN but there was no association of this genotype with renal function or renal survival.
|
20231199 |
2010 |
Lupus Nephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Incubating IL-20 with mesangial cells upregulated the transcripts of CCL2 (MCP-1), CCL5 (RANTES), CXCL10 (IP-10), IL-6, iNOS, and ROS, all of which are involved in the pathogenesis of lupus nephritis.
|
18771958 |
2008 |
Lupus Nephritis
|
0.100 |
AlteredExpression
|
disease |
LHGDN |
Larger prospective studies of paediatric LN are required to further evaluate MCP-1 and other markers of disease progression.
|
18495743 |
2008 |
Lupus Nephritis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In this study, we examined the role of a functional monocyte chemoattractant protein 1 (MCP-1) polymorphism in SLE and LN.
|
15188361 |
2004 |
Lupus Nephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study we assessed the significance of the MCP-1 gene in determination of the histological phenotype in lupus nephritis.
|
15119544 |
2004 |
Lupus Nephritis
|
0.100 |
GeneticVariation
|
disease |
LHGDN |
In this study, we examined the role of a functional monocyte chemoattractant protein 1 (MCP-1) polymorphism in SLE and LN.
|
15188361 |
2004 |